PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
– Strong Q3 2026 performance with total revenue of $358 million, including $276 million of product revenue – – Full-year 2026 expected total revenue increased to $1.29 to $1.32 billion, with full-year product revenue guidance raised to $960 to $990 million – – Sephience™ (sepiapterin) Q3...


